(Q41240306)

28 September 2017

title

Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load (English)

1 reference

28 September 2017

0 references

1 reference

1 reference

1 reference

1

1 reference

28 September 2017

Junggyu Lee

2

1 reference

28 September 2017

Juna Goo

3

1 reference

28 September 2017

Kyunga Kim

4

1 reference

28 September 2017

Geum-Youn Gwak

5

1 reference

28 September 2017

Yong-Han Paik

6

1 reference

28 September 2017

Moon Seok Choi

7

1 reference

28 September 2017

Joon Hyeok Lee

8

1 reference

28 September 2017

Kwang Cheol Koh

9

1 reference

28 September 2017

Byung Chul Yoo

10

1 reference

28 September 2017

Seung Woon Paik

11

1 reference

28 September 2017

language of work or name

English

0 references

publication date

11 May 2015

1 reference

28 September 2017

1 reference

28 September 2017

volume

62

1 reference

28 September 2017

issue

3

1 reference

28 September 2017

page(s)

694-701

1 reference

KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

28 September 2017

cites work

1 reference

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

21 January 2018

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma

21 January 2018

1 reference

[Practice guidelines for management of hepatocellular carcinoma 2009].

21 January 2018

1 reference

Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease.

21 January 2018

1 reference

Marginal structural models and causal inference in epidemiology

21 January 2018

1 reference

Side effects of long-term oral antiviral therapy for hepatitis B.

21 January 2018

1 reference

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

21 January 2018

1 reference

Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease

21 January 2018

1 reference

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology.

21 January 2018

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

DNA-guided hepatitis B treatment, viral load is essential, but not sufficient

21 January 2018

1 reference

Role of hepatitis B surface antigen (HBsAg) in identifying true inactive HBsAg carriers infected with genotype C hepatitis B virus

21 January 2018

1 reference

High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load

21 January 2018

1 reference

Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea

21 January 2018

1 reference

Hepatitis B virus infection

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.27889

1 reference

28 September 2017

1 reference